Summary of COVID-19 brexanolone studies

1. Brown et al., A Study of Brexanolone for Acute Respiratory Distress Syndrome Due to COVID-19

29 patient brexanolone ICU RCT: 14% higher mortality (p=1) and no change in progression (p=1).
RCT 28 ventilated patients, showing no significant difference with brexanolone treatment.
Jul 2022, NCT04537806, https://clinicaltrials.gov/study/NCT04537806, https://c19p.org/brown3